Speech Handicap Index in patients with oral and pharyngeal cancer: Better understanding of patients' complaints

Rinkel, Rico N. P. M.; Leeuw, Irma M. Verdonck‐de; Reij, Ellen J. van; Aaronson, Neil K.; Leemans, C. René

doi:10.1002/hed.20795

Cited by 116 publications

(104 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The English language version of SHI has shown high values of reliability and validity scores that are parallel to the Dutch version, 2 indicating it to be a good tool for evaluating the impact of speech impairment in patients with head and neck cancer. Patients can easily complete it while waiting for their turn to come in the outpatient department.…”

Section: Discussionmentioning

confidence: 98%

“…The development of the Dutch version of the SHI was largely based on the widely used and popular voice-specific scale the ''Voice Handicap Index'' (VHI) 32 by Rinkel et al 2 Consequently, our English version of SHI (Appendix) is on the same lines. 32 It has 30 well-constructed questions to evaluate the patient's speech and psychosocial functions.…”

Section: Methodsmentioning

confidence: 99%

“…[7][8][9][10] Nowhere else is this more obvious than in cancers involving the oral cavity and oropharynx. 1,2 The presence of posttreatment speech problems in patients with oral and oropharyngeal cancers has been well documented in the literature by both prospective and retrospective studies. [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] In accord with recent estimates, nearly 50% of oral and oropharyngeal cancer patients encounter speech problems in their day-to-day life, 2 which is not surprising because the tumor and its treatment often have a detrimental impact on the functioning of important speech articulators (tongue, alveolar ridge, hard and soft palate, and floor of mouth) in the oral cavity and the oropharynx.…”

mentioning

confidence: 99%

“…[1][2][3][4][5][6] Patients often report speech deterioration, swallowing difficulties, and facial appearance changes that may ultimately result in psychosocial problems. [7][8][9][10] Nowhere else is this more obvious than in cancers involving the oral cavity and oropharynx.…”

mentioning

confidence: 99%

See 3 more Smart Citations

First report on the reliability and validity of speech handicap index in native English‐speaking patients with head and neck cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

First report on the reliability and validity of speech handicap index in native English‐speaking patients with head and neck cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…More recently, Lazarus et al (2014) noted that HNC survivors' reported impaired speech, as measured by the Speech Handicap Index (Rinkel, Verdonck-de Leeuw, van Reij, Aaronson, & Leemans, 2008), following chemoradiotherapy. This was in contrast to clinicianperceptions of complete intelligibility, both before chemoradiotherapy treatment, and at 3 and 6 months post-treatment.…”

Section: Introductionmentioning

confidence: 99%

Communication changes following non-glottic head and neck cancer management: The perspectives of survivors and carers

Nund¹,

Rumbach²,

Debattista³

et al. 2015

International Journal of Speech-Language Pathology

View full text Add to dashboard Cite

Assessment of Neurocognitive Impairment and Speech Functioning Before Head and Neck Cancer Treatment

Piai

Prins²,

Leeuw

et al. 2019

JAMA Otolaryngol Head Neck Surg

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Head and neck cancer (HNC) and its treatment may negatively alter neurocognitive and speech functioning. However, the prevalence of neurocognitive impairment among patients with HNC before treatment is poorly studied, and the association between neurocognitive and speech functioning is unknown, which hampers good interpretability of the effect of HNC treatment on neurocognitive and speech function.OBJECTIVES To document neurocognitive functioning in patients with HNC before treatment and to investigate the association between neurocognitive and speech functioning. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of newly diagnosed patients with HNC before treatment using a large sample obtained in a nationwide, multicenter setting (Netherlands Quality of Life and Biomedical Cohort Study in Head and Neck Cancer [NET-QUBIC] project). MAIN OUTCOME AND MEASURESObjective neuropsychological measures of delayed recall, letter fluency, and executive functioning, as well as patient-reported outcome measures on neurocognitive speech and functioning, were collected before treatment. RESULTSIn total, 254 patients with HNC participated (71.7% male), with a mean (SD) age of 62 (10) years. The response rate ranged from 81.9% (208 of 254) to 84.6% (215 of 254). Objective neurocognitive measures indicated that 4.7% (10 of 212) to 15.0% (32 of 214) of patients were initially seen with moderate to severe cognitive impairment. Mild to moderate impairment was found in 12.3% (26 of 212) to 26.2% (56 of 214) of patients. The most altered domains were delayed recall and letter fluency. Seven percent (15 of 208) of the patients reported high levels of everyday neurocognitive failure, and 42.6% (89 of 209) reported speech problems. Objective neurocognitive function was not significantly associated with patient-reported neurocognitive or speech functioning, but the results from patient-reported outcome measures were significantly correlated. CONCLUSIONS AND RELEVANCEResults of this study demonstrate a high prevalence of impaired speech functioning among patients with HNC before treatment, which is in line with previous findings. A novel finding is that neurocognitive impairment is also highly prevalent as objectively measured and as self-perceived. Understanding the reason why patients with HNC are initially seen with neurocognitive impairment before the start of treatment is important because this impairment may complicate patient-clinician interaction and alter treatment adherence and because treatment itself may further worsen cognitive functioning. In addition, low self-perceived neurocognitive and speech functioning before treatment may decrease a patient's confidence in communicative participation and perceived quality of life. Disentangling the associations between objective and patient-reported neurocognitive and speech functions is an important area for future research.

show abstract

Speech Handicap Index in patients with oral and pharyngeal cancer: Better understanding of patients' complaints

Abstract: Results of this initial psychometric study indicate that the SHI is a reliable and valid questionnaire for assessing speech problems. Additional research is needed to evaluate responsiveness of the questionnaire to changes in speech-related problems over time.

Cited by 116 publications

References 37 publications

First report on the reliability and validity of speech handicap index in native English‐speaking patients with head and neck cancer

First report on the reliability and validity of speech handicap index in native English‐speaking patients with head and neck cancer

Communication changes following non-glottic head and neck cancer management: The perspectives of survivors and carers

Assessment of Neurocognitive Impairment and Speech Functioning Before Head and Neck Cancer Treatment

Contact Info

Product

Resources

About